ATN ASTROCYTES TO NEURONS Trademark

Trademark Overview

On Wednesday, January 19, 2022, a trademark application was filed for ATN ASTROCYTES TO NEURONS with the United States Patent and Trademark Office. The USPTO has given the ATN ASTROCYTES TO NEURONS trademark a serial number of 97227503. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, April 7, 2025. This trademark is owned by NeuExcell Therapeutics Inc.. The ATN ASTROCYTES TO NEURONS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, physical injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, infection, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, cerebral venous sinus thrombosis, retinal disease and other disease arising from neuronal damage; and testing, inspection, research or development of pharmaceutical preparations for gene therapy or small molecule treatment
atn astrocytes to neurons

General Information

Serial Number97227503
Word MarkATN ASTROCYTES TO NEURONS
Filing DateWednesday, January 19, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, April 7, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 14, 2023

Trademark Statements

NOT AVAILABLE"ASTROCYTES TO NEURONS"
Goods and ServicesResearch and development of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, physical injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, infection, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, cerebral venous sinus thrombosis, retinal disease and other disease arising from neuronal damage; and testing, inspection, research or development of pharmaceutical preparations for gene therapy or small molecule treatment

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 10, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNeuExcell Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPhiladelphia, PA 19108
Party NameNeuExcell Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPhiladelphia, PA 19108

Trademark Events

Event DateEvent Description
Saturday, January 22, 2022NEW APPLICATION ENTERED
Tuesday, January 25, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 1, 2022ASSIGNED TO EXAMINER
Tuesday, August 2, 2022NON-FINAL ACTION WRITTEN
Tuesday, August 2, 2022NON-FINAL ACTION E-MAILED
Tuesday, August 2, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 10, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, January 10, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, January 10, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, January 10, 2023EXAMINER'S AMENDMENT ENTERED
Thursday, January 12, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 14, 2023PUBLISHED FOR OPPOSITION
Wednesday, January 25, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, July 26, 2023SOU EXTENSION 1 FILED
Wednesday, July 26, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, July 26, 2023SOU EXTENSION 1 GRANTED
Tuesday, March 5, 2024SOU TEAS EXTENSION RECEIVED
Friday, July 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 5, 2024SOU EXTENSION 2 GRANTED
Wednesday, August 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 5, 2024SOU EXTENSION 2 FILED
Wednesday, March 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 28, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, August 28, 2024SOU EXTENSION 3 GRANTED
Wednesday, August 28, 2024SOU EXTENSION 3 FILED
Monday, April 7, 2025SOU TEAS EXTENSION RECEIVED
Monday, April 7, 2025SOU EXTENSION 4 FILED
Monday, April 7, 2025SOU EXTENSION 4 GRANTED
Tuesday, April 8, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

neurons astrocytes disease injury myelopathy brain cerebral traumatic atrophy cord embolism research